Tumor Necrosis Factor (TNF) Inhibitors Market Is Expected To Reach US$ 181,139.7 Mn By 2026

The latest market report published by Acute Market Reports, “Tumor Necrosis Factor (TNF) Inhibitors Market By Drug Type (Adalimumab (Humira), Certolizumab (Cimzia), Etanercept (Enbrel), Golimumab (Simponi), Infliximab (Remicade)), By Application (Crohn’s Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ulcerative Colitis, Ankylosing Spondylitis, Hidradenitis Suppurativa, Uveitis, Juvenile Arthritis) – Growth, Future Prospects, and Competitive Analysis, 2018 -2026″The market for tumor necrosis factor inhibitors was valued at US$ 43,394.4 million in 2017 and is anticipated to reach US$ 181,139.7 million by 2026, increasing to CAGR by 16.5 per cent from 2018 to 2026.

Browse the full report at “Tumor Necrosis Factor (TNF) Inhibitors Market”

Market Insights Global market for tumor necrosis factor (TNF) inhibitors was valued at US$ 43,394.4 million in 2017 and is expected to achieve US$ 181,139.7 by 2026 with a CAGR of 16.5 per cent during the forecast period. Only five authorized TNF inhibitors currently dominate the industry, namely adalimumab, certolizumab, etanercept, golimumab and infliximab. The comprehensive use of these approved drugs under multiple autoimmune conditions guarantees continued market growth during the forecast period from 2018 to 2026. The approval of biosimilars would contribute to the profitability of this industry. Biosimilars will increase competition in the market for TNF inhibitors, as several industrial players are presently investing in their growth. High incidence of chronic circumstances such as Crohn’s disease, ulcerative colitis, plaque psoriasis, rheumatoid arthritis & others, ongoing study operations in the development of target-based biologics, the provision of structured refund strategies and a increasing tendency towards cost-effective biosimilars in developing countries contribute to the remunerative development of this industry. In addition, the increasing incidence of chronic autoimmune diseases such as Crohn’s disease, rheumatoid arthritis, plaque psoriasis and ulcerative colitis increases the need for targeted therapies such as TNF inhibitors.

The market for TNF inhibitors has been segmented based on a drug type that includes authorized TNF inhibitors as stated above and numerous applications of TNF inhibitors including Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ulcerative colitis, ankylosing spondylitis, hidradenitis suppurativa, uveitis and juvenile arthritis. Crohn’s disease segment is expected to have the highest CAGR due to its increasing incidence across geography and increasing knowledge of the efficacy of TNF inhibitors. According to the Centers for Disease Control and Prevention (CDC), approximately 201 instances of Crohn’s disease per 100,000 adolescents were reported in 2015. Prevalence will continue to increase during the forecast period due to the increasing implementation of unsanitary dietary habits.

Based on the geographical demarcation, North America dominated the market in 2017 with a market share of more than 40% and expected to keep this position throughout the forecast era. The patent exclusivity of authorized long-term TNF inhibitors guarantees maximum profitability in this industry. Asia Pacific showed the highest development in the forecast period. Increased incidence of autoimmune diseases, enhanced awareness of the efficacy and accessibility of TNF inhibitors, enhanced investment in biosimilars by multiple industrial players and enhanced support from biosimilar approval regulators are anticipated to catalyze general market growth in Asia Pacific.

TNF inhibitors market comprise of industrial players with maximum global outreach namely, Abbvie, Inc., Amgen, Inc., Biocad Biopharmaceutical Co., Boehringer Ingelheim Pharmaceuticals, Inc., EPIRUS Biopharmaceuticals, Inc., Innovent Biologics, Inc., Janssen Biotech, Inc., Merck & Co., Inc., Novartis A.G., Pfizer, Inc., Shanghai Henlius Biotech, Inc. and UCB S.A.

Key Market Movements:

• Globally tumor necrosis factor inhibitors market witnesses a remunerative growth with a CAGR of 16.5 % during the forecast period from 2018 to 2026
• Constant research activities in label expansion of TNF inhibitors enhancing its application across various disease areas thus catalyzing the market growth
• Rising prevalence of autoimmune disease across geographies and the use of TNF inhibitors for multiple autoimmune conditions catalyzing the market growth
• Biosimilars are expected to increase market competition in the near future and ensure incessant growth  during the forecast period from 2018 to 2026

By Drug Type Segment (2016–2026; US$ Mn)

• Adalimumab
• Certolizumab
• Etanercept
• Golimumab
• Infliximab
• Pipeline Analysis
  • Phase III Molecules
    • IBI303
    • HLX03
    • BCD-057
    • M923
  • Phase I & Phase II Molecules

By Application Segment (2016–2026; US$ Mn)

• Crohn’s Disease
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Plaque Psoriasis
• Ulcerative Colitis
• Ankylosing Spondylitis
• Hidradenitis Suppurativa
• Uveitis
• Juvenile Arthritis

By Geography Segment (2016–2026; US$ Mn)

• North America
• Europe
• Asia Pacific (APAC)
• Middle East & Africa (MEA)
• Latin America